A phase I study of XL184, a RET, VEGFR2, and MET kinase inhibitor, in patients (pts) with advanced malignancies, including pts with medullary thyroid cancer (MTC) - Salgia, R; Sherman, S; Hong, DS (J Clin Oncol, 2008)
abstr 3522.